ADHD, or Attention Deficit Hyperactivity Disorder, affects both children and adults and is commonly treated with medications like methylphenidate (Ritalin), which helps boost focus by increasing levels of norepinephrine and dopamine in the brain.

Researchers aimed to explore whether starting medication shortly after an ADHD diagnosis could lower death rates among those with the disorder, given prior data suggesting various associated risks.

Researchers examined medical records from Sweden, selecting individuals aged 6 to 64 years diagnosed with ADHD between 2007 and 2018. None had taken ADHD medications before diagnosis. Follow-up began right after diagnosis and continued until death, leaving the country, a two-year period, or end of 2020.

They checked if ADHD medications were started within three months and tracked deaths over two years, distinguishing between natural and unnatural death causes.

The study included over 148,000 people with ADHD, a little over half started medication soon after diagnosis. Those who began treatment had a lower risk of dying within two years than those who did not. This suggests starting ADHD medication can decrease overall mortality risk.

The reduction was more apparent with unnatural causes of death, like accidents. However, starting medication didn't significantly affect the rate of deaths from natural causes.

The findings suggest that for individuals diagnosed with ADHD, beginning medication may reduce their chances of dying, especially from unnatural causes. The study highlights the potential life-saving benefits of medication for ADHD patients.

While the results are promising, they mainly pertain to reducing mortality from unnatural causes, indicating the importance of proper management of ADHD symptoms to enhance overall safety and longevity.